employer coverage glp-1 news october 2025 Approaches to How Employers Can Manage GLP-1

Study results: what did they find

Discover a new, effective approach to managing weight and improving health.

Food and Drug Administration Adverse Event Reporting System (FAERS) database has revealed that glucagon-like peptide 1 receptor agonists (GLP-1RAs) do not appear to...

Several forces will shape this trajectory: Patent Expiry and Pricing: Semaglutides Loss of Exclusivity Off-patent semaglutide will be a defining event in 2026 as it begins to come off patent in several countries

Restless leg syndrome is a common condition that affects the nervous system, resulting in uncomfortable sensations that cause an overwhelming urge to move the legs or arms.

Protein Description